EXHIBIT
      31.2








**CERTIFICATION
      PURSUANT TO RULE 13a-14(a)/15d-14(a)**


**OF
      THE SECURITIES EXCHANGE ACT OF 1934**





In
        connection with the Quarterly Report of DOR BioPharma, Inc. (the “Company”) on
        Form 10-QSB for the fiscal quarter ended March
        31,
        2007 ,
        as
        filed with the Securities and Exchange Commission on the date hereof, I,
        Evan
        Myrianthopoulos, Chief Financial Officer of the Company, certify, pursuant
        to
        Rule 13a-14(a) of the Securities Exchange Act of 1934, that:
 
 1.
        I have
        reviewed the Quarterly Report on Form 10-QSB of the Company for the fiscal
        quarter ended March
        31,
        2007 ;
 
 2.
        Based
        on my knowledge, this report does not contain any untrue statement of a material
        fact or omit to state a material fact necessary to make the statements made,
        in
        light of the circumstances under which such statements were made, not misleading
        with respect to the period covered by this report;
 
 3.
        Based
        on my knowledge, the financial statements, and other financial information
        included in this report, fairly present in all material respects the financial
        condition, results of operations and cash flows of the registrant as of,
        and
        for, the periods presented in this report;
 
 4.
        The
        registrant’s other certifying officer and I are responsible for establishing and
        maintaining disclosure controls and procedures (as defined in Exchange Act
        Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
 
 (a)
        Designed such disclosure controls and procedures, or caused such disclosure
        controls and procedures to be designed under our supervision, to ensure that
        material information relating to the registrant, including its consolidated
        subsidiaries, is made known to us by others within those entities, particularly
        during the period in which this report is being prepared;
 
 (b)
        Evaluated the effectiveness of the registrant’s disclosure controls and
        procedures and presented in this report our conclusions about the effectiveness
        of the disclosure controls and procedures, as of the end of the period covered
        by this report based on such evaluation; and
 
 (c)
        Disclosed in this report any change in the registrant’s internal control over
        financial reporting that occurred during the registrant’s most recent fiscal
        quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
        that has materially affected, or is reasonably likely to materially affect,
        the
        registrant’s internal control over financial reporting; and
 
 5.
        The
        registrant’s other certifying officer and I have disclosed, based on our most
        recent evaluation of internal control over financial reporting, to the
        registrant’s auditors and the audit committee of the registrant’s board of
        directors (or persons performing the equivalent functions):
  (a)  All
        significant deficiencies and material weaknesses in the design or operation
        of
        internal control over financial reporting which are reasonably likely to
        adversely affect the registrant’s ability to record, process, summarize and
        report financial information; and
 
 (b)  Any
        fraud, whether or not material, that involves management or other employees
        who
        have a significant role in the registrant’s internal control over financial
        reporting.
 
 
 
 
 Date: March
        15,
        2007
   By: /s/
      Evan Myrianthopoulos


Evan
      Myrianthopoulos


Chief
      Financial Officer